sermorelin vs glp-1 glp 1 Sermorelin Therapy GLP-1/GIP Shortage Updates | OrderlyMeds

Strongest weight-loss data in its class.

This analysis was part of the IMI-Stratification of Obesity Phenotypes to Optimize Future Obesity Therapy (IMI-SOPHIA) project

Discover strategies to manage this side effect from weight loss treatments.

Discover how your intestines make this crucial hormone, what factors affect its production, and how natural GLP-1 differs from medications like Ozempic and Wegovy.

A UCLA study published in ACR Open Rheumatology found that GLP-1 receptor agonists such as semaglutide and tirzepatide may reduce rheumatoid arthritis activity and cardiovascular risk factors in people with obesity, suggesting potential dual benefits for metabolic and inflammatory health.

Tirzepatide (Zepbound/Mounjaro): A dual GLP-1/GIP receptor agonist undergoing evaluation for MASH after demonstrating significant liver fat reduction in studies.Retatrutide: A "triple agonist" targeting GLP-1, GIP, and glucagon (GCGR) receptors, which has shown "unprecedented" efficacy in weight loss and is being evaluated for metabolic diseases including MASH